Copyright
©The Author(s) 2023.
World J Clin Cases. Oct 26, 2023; 11(30): 7350-7362
Published online Oct 26, 2023. doi: 10.12998/wjcc.v11.i30.7350
Published online Oct 26, 2023. doi: 10.12998/wjcc.v11.i30.7350
Table 4 Efficacy of different comparisons of drugs for Oswestry disability index by weighted mean differences and corresponding 95%CI
| Alendronate | 11.85 (-0.98, 24.15) | 0.17 (-17.13, 17.05) | -3.57 (-16.04, 8.89) | -8.56 (-28.58, 11.16) | 7.85 (-12.25, 27.17) |
| -11.85 (-24.15, 0.98) | Placebo | -11.68 (-26.12, 2.94) | -15.43 (-27.71, -2.7) | -20.42 (-40.08, -0.43) | -4.01 (-19.31, 11.09) |
| -0.17 (-17.05, 17.13) | 11.68 (-2.94, 26.12) | Risedronate | -3.76 (-18.1, 10.98) | -8.74 (-29.92, 12.56) | 7.67 (-13.54, 28.7) |
| 3.57 (-8.89, 16.04) | 15.43 (2.7, 27.71) | 3.76 (-10.98, 18.1) | Teriparatide | -4.99 (-20.54, 10.47) | 11.44 (-8.49, 30.78) |
| 8.56 (-11.16, 28.58) | 20.42 (0.43, 40.08) | 8.74 (-12.56, 29.92) | 4.99 (-10.47, 20.54) | Teriparatide + denosumab | 16.43 (-8.94, 41.21) |
| -7.85 (-27.17, 12.25) | 4.01 (-11.09, 19.31) | -7.67 (-28.7, 13.54) | -11.44 (-30.78, 8.49) | -16.43 (-41.21, 8.94) | Zoledronic acid |
- Citation: He XY, Chen HX, Zhao ZR. Efficacy and safety of different anti-osteoporotic drugs for the spinal fusion surgery: A network meta-analysis. World J Clin Cases 2023; 11(30): 7350-7362
- URL: https://www.wjgnet.com/2307-8960/full/v11/i30/7350.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i30.7350